Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
NCT05538247Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Apr 2023
- Primary completion
- Dec 2025
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial comparing S. boulardii CNCM I-745 Group with Placebo Group (2 arms). Primary endpoints: Permeability assays, Change in serum zonulin at 14 days and 4 more. Started Apr 2023; status: completed.
02
Drugs
saccharomyces boulardii
Beyond the preview
Go deeper on NCT05538247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05538247.